COMIRNATY is used to prevent COVID-19 disease caused by the SARS-CoV-2 virus in people aged 6 months and older.
Jump to:
Number of patients vaccinated around the world
BioNTech’s research of mRNA
Pfizer’s history in developing vaccines
COMIRNATY
COMIRNATY Original & Omicron BA.4/BA.5
COMIRNATY
How does COMIRNATY work?
Safety information
Number of patients vaccinated around the world
doses in Canada
Over 102 million doses have been administered in Canada, with over 95% of eligible Canadians receiving at least one dose.
additional doses in Canada
Over 19 million 3rd doses have been administered to Canadians who have completed their primary series.
doses worldwide
Around the world, more than 4.3 billion
doses have been given – and those numbers continue to increase.
Pfizer partnered with BioNTech due to this company's dedication to scientific innovation and leadership, and its rich history of mRNA vaccine research. While clinical studies for the Pfizer-BioNTech COVID-19 mRNA vaccine began in 2020, BioNTech had been working with the mRNA technology for more than 20 years.
Genetic sequencing of the virus
Start of global development program
Phase 1/2 studies
Phase 2/3 studies
Authorization
for use
Ongoing studies
Pfizer is committed to bringing patients timely access to quality healthcare through innovative medicines backed by strong science and supportive patient experiences.
Pfizer’s legacy in vaccines is rooted in its long-standing presence
in preventive solutions and vaccine development.
Their portfolio, including those of their legacy companies, is comprehensive and includes vaccines that are administered through routine immunization programs.
Smallpox vaccine developed at the Company’s Lancaster County Vaccine Farm*
* Wyeth
The Company introduces a combined vaccine for the prevention of diphtheria,
tetanus and pertussis (DTP)†
† Lederle Laboratories
First to license an oral form of live trivalent poliovirus†
† Lederle Laboratories
First to license a conjugate-based vaccine for Haemophilus influenzae type b‡
‡ Praxis Biologics
First to license a meningococcal serogroup C conjugate vaccine§
§ Wyeth Lederle Vaccines and Pediatrics
First to license a 7-valent pneumococcal conjugate vaccine§
§ Wyeth Lederle Vaccines and Pediatrics
First to license a 13-valent pneumococcal conjugate vaccine¶
¶ Pfizer
First to license a meningococcal group B vaccine¶
¶ Pfizer
Pfizer’s innovative vaccine portfolio is driven by
scientific research and development.
COMIRNATY is a vaccine used to prevent COVID-19 disease caused by the SARS-CoV-2 virus. They can be given to people aged 6 months and older.
12 Years of Age and Older
COMIRNATY is injected into a muscle of the upper arm.
You will receive 1 injection, regardless of whether you have received a COVID-19 vaccine before.
If you were previously vaccinated with a COVID-19 vaccine, you should not receive a dose of COMIRNATY until 3 to 6 months after the most recent dose.
5 Years Through 11 Years
COMIRNATY is injected into a muscle of the upper arm.
Your child will receive 1 injection, regardless of whether your child have received a COVID-19 vaccine before.
If your child was previously vaccinated with a COVID-19 vaccine, your child should not receive a dose of COMIRNATY until at least 6 months after the most recent dose.
Ages 6 Months to 4 Years
COMIRNATY is injected into a muscle of your child’s thigh or upper arm.
If your child has not completed a COVID-19 primary vaccination course, your child will receive a maximum of 3 injections (the total number of doses required as the primary course). It is recommended to receive the second dose 3 weeks after the first dose followed by a third dose at least 8 weeks after the second dose to complete the three-dose course. If your child has started a three-dose course with COMIRNATY Omicron XBB.1.5 , they may complete the three-dose course with COMIRNATY .
If your child has previously completed a COVID-19 primary vaccination course, your child will receive 1 injection. If your child was previously vaccinated with a COVID-19 vaccine, they should not receive a dose of COMIRNATY until at least 6 months after the most recent dose.
The National Advisory Committee on Immunization (NACI) notes that the Pfizer-BioNTech COVID-19 vaccine is efficacious against symptomatic laboratory-confirmed COVID-19 disease when provided as a two-dose schedule.
It is very important that you return for all subsequent doses of the vaccine.
The vaccine may not work as well if you do not receive all doses, as recommended.
As with any vaccine, COMIRNATY may not fully protect all those who receive it.
Safety information:
COMIRNATY should not be used if you/your child have had a severe allergic reaction after a previous dose of any COMIRNATY vaccine, or are allergic to any of the ingredients in the vaccine.
If you/your child have any symptoms that could be due to COVID-19, talk with your healthcare professional about you/your child's symptoms and getting a COVID-19 test. You/your child's healthcare professional will advise you when you/your child are able to receive the vaccine.
Before you/your child receive COMIRNATY, talk to your healthcare professional if you/your child:
Please note:
Very common side effects (may affect more than 1 in 10 people) include: irritability (6 months to <2 years), injection site pain/tenderness, swelling, tiredness, headache, muscle pain, chills, joint pain, fever, diarrhea. Common side effects (may affect more than 1 in 100 and up to 1 in 10 people) include: injection site redness (“very common” in 6 months to <12 years), nausea, vomiting, rash (6 months to <2 years), enlarged lymph nodes (more frequently observed after the booster dose). Uncommon side effects (may affect more than 1 in 1,000 and up to 1 in 100 people) include: feeling unwell, arm pain, feeling weak or lack of energy/sleepy, decreased appetite (“very common” for 6 months to <2 years), excessive sweating, night sweats. There is a remote chance that COMIRNATY could cause a severe allergic reaction. A severe allergic reaction would usually occur within a few minutes to one hour after getting a dose of COMIRNATY. For this reason, your vaccination provider may ask you/your child to stay at the place where the vaccine was received for monitoring after vaccination. Should you/your child develop any serious symptoms or symptoms that could be an allergic reaction, seek medical attention right away. Symptoms of an allergic reaction include: hives (bumps on the skin that are often very itchy), swelling of the face, tongue or throat, difficulty breathing, a fast heartbeat, or dizziness and weakness.